Laura E. Niklason - 18 Nov 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
18 Nov 2024
Net transactions value
-$6,606,799
Form type
4
Filing time
20 Nov 2024, 19:06:35 UTC
Previous filing
11 Sep 2024
Next filing
21 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale $3,601,604 -811,172 -25% $4.44 2,419,712 18 Nov 2024 By Ayabudge LLC F1, F2
transaction HUMA Common Stock Sale $1,855,172 -427,459 -18% $4.34 1,992,253 19 Nov 2024 By Ayabudge LLC F1, F3
transaction HUMA Common Stock Sale $1,150,024 -261,369 -13% $4.40 1,730,884 20 Nov 2024 By Ayabudge LLC F1, F4
holding HUMA Common Stock 242,054 18 Nov 2024 Direct
holding HUMA Common Stock 1,148,240 18 Nov 2024 By The Niklason Living Trust
holding HUMA Common Stock 510,161 18 Nov 2024 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.